A great option for elderly patients with locally invasive bladder cancer, BOAI-CDDP-radiation (OMC regimen)

Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar

Johansson SL and Cohen SM: Epidemiology and etiology of bladder cancer. Semin Surg Oncol. 13:291–298. 1997. View Article : Google Scholar : PubMed/NCBI

Tran E, Souhami L, Tanguay S and Rajan R: Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer. Am J Clin Oncol. 32:333–337. 2009. View Article : Google Scholar : PubMed/NCBI

Weizer AZ, Joshi D, Daignault S, et al: Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol. 177:1287–1293. 2007. View Article : Google Scholar : PubMed/NCBI

Hoshi S, Shintaku I, Suzuki K, et al: Bladder preservation by internal iliac arterial infusion chemotherapy and irradiation in T3 bladder carcinoma patients over the age of 70 years. Tohoku J Exp Med. 192:249–258. 2000.PubMed/NCBI

Kaufman DS, Winter KA, Shipley WU, et al: The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 5:471–476. 2000.

Rodel C, Grabenbauer GG, Kuhn R, et al: Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 20:3061–3071. 2002. View Article : Google Scholar : PubMed/NCBI

Shipley WU, Winter KA, Kaufman DS, et al: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 16:3576–3583. 1998.

Tester W, Caplan R, Heaney J, et al: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 14:119–126. 1996.

Hagan MP, Winter KA, Kaufman DS, et al: RTOG 97-06: initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 57:665–672. 2003.PubMed/NCBI

Kaufman DS, Winter KA, Shipley WU, et al: Phase I–II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 73:833–837. 2009.

Azuma H, Inamoto T, Ibuki N, et al: Novel bladder preservation therapy for locally invasive bladder cancer: combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. Int J Oncol. 37:773–785. 2010. View Article : Google Scholar

Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG and Morrow M: AJCC Cancer Staging Manual. 6th edit. Springer Verlag; New York, NY: 2002, View Article : Google Scholar

Ficcara V, Dalpiaz O, Alrabi N, Novara G, Galfano A and Artibani W: Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int. 95:786–790. 2005. View Article : Google Scholar : PubMed/NCBI

Azuma H, Inamoto T, Ibuki N, et al: Utility of the novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen), for elderly patients with invasive bladder cancer. Int J Oncol. 38:13–24. 2011.PubMed/NCBI

Nielsen ME, Shariat SF, Karakiewicz PI, et al: Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol. 51:699–708. 2007. View Article : Google Scholar

Collins JM: Pharmacokinetic rationale for intraarterial therapy. Cancer Chemotherapy, Challenges for the Future. 4. Kimura K: Excerpta Medica; Amsterdam: 1989

Mitsuzane K, Kawabata M, Terada M, Nomura S, Sato M and Yamada R: Balloon-occluded arterial infusion as chemotherapy in bladder cancer-long-term results. Gan To Kagaku Ryoho. 17:1701–1704. 1990.(In Japanese).

Cvitkovic E, Spaulding J, Bethune V, Martin J and Whitmore WF: Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer. 39:1357–1361. 1977. View Article : Google Scholar : PubMed/NCBI

Douple EB and Richmond RC: A review of platinum complex biochemistry suggests a rationale for combined platinum-radiotherapy. Int J Radiat Oncol Biol Phys. 8:1335–1339. 1979. View Article : Google Scholar : PubMed/NCBI

Abbott DW, Freeman ML and Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst. 90:978–985. 1998. View Article : Google Scholar : PubMed/NCBI

Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA and Repta AJ: Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 63:1515–1521. 1979.PubMed/NCBI

Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ and Sternson LA: Clinical kinetics on intact cisplatin and some related species. Clin Pharmacol Ther. 29:658–664. 1981. View Article : Google Scholar : PubMed/NCBI